JP Morgan 2018 | Biotech Strategy Blog

Highlights of JPM18 Healthcare Day 2

It’s Tuesday at the 2018 JP Morgan Healthcare conference in San Francisco…

Rain in San Francisco

Each day of #JPM18 we’re doing a rolling blog post which we’re updating throughout the day with commentary and insights on the company presentations we’re covering.

While we’re not giving a blow-by-blow account, we will be commenting on noteworthy news, and what we learn about pharma/biotech corporate strategy going into 2018.

For those of you who like to catch up with the final summary of each day’s highlights, you can read our post and commentary around Day 1 here (Link).

We’ve also posted a new interview with the Syros CEO, Dr Nancy Simonian, as part of our ASH/JPM18 crossover series. Syros are presenting on Thursday but had data last month at both SABCS and ASH.

To learn more and get a heads up on our latest insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Highlights of JPM18 Healthcare Conf Day 1

It’s Day 1 of the JP Morgan Healthcare Conference in San Francisco

In light of the success of our rolling blog from last years’ JPM conference (link to #JPM17 coverage), we’ve decided to repeat the concept again this year.

Throughout the day (schedule permitting) we’ll be updating the post with commentary around news from San Francisco that catches our attention.

If you want to follow along yourself and listen to the company presentations, here’s the link to the JPM18 webcasts and conference agenda (link).

As an aside, in our coverage we will be using JPM followed by the last two digits of the year of the meeting i.e. #JPM18, last year it was #JPM17, and the year before that #JPM16. This is how the “BioTwitter” community commonly refers to the meeting, and we will be continuing that tradition, notwithstanding the fact that JP Morgan have announced a different “official” Twitter hashtag.

To read our rolling #JPM18 blog, subscribers can log-in or you can purchase access to BSB Premium Content.

This content is restricted to subscribers

Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy